About Vektor Pharma

Who We Are

Vektor Pharma TF GmbH is a German pharmaceutical development company specializing in advanced oral thin film (ODF) drug delivery systems.


As a wholly owned subsidiary of BioNxt Solutions Inc., we focus exclusively on the research, formulation development, and technical project management of thin film dosage forms. Our expertise spans from early feasibility studies and formulation optimization to the preparation of clinical trial prototypes in collaboration with GMP-qualified partners.

We exist to transform innovative drug concepts into scalable, patient-friendly thin film solutions — combining pharmaceutical science, engineering precision, and regulatory awareness to deliver measurable therapeutic value.

Our Mission

To redefine how active pharmaceutical ingredients are delivered, absorbed, and experienced through next-generation oral thin film technologies that offer precision, flexibility, and superior patient compliance.

What We Do

Formulation Development

Custom, patent-protected oral thin film formulations designed to optimize bioavailability, stability, and dosing precision across a wide range of active ingredients.

Proprietary ODF Platforms

Development of intellectual property–backed oral thin film platforms and delivery concepts adaptable to diverse APIs and therapeutic indications.

Clinical & Technical Development

Preparation of clinical trial prototypes and end-to-end coordination of development programs, from pre-formulation and feasibility through scale-up and regulatory preparation.

Strategic Collaboration

Partnering with pharmaceutical, biotech, nutraceutical, and specialty healthcare companies to co-develop differentiated thin film products with long-term commercial value.

Our Team

Our multidisciplinary team combines expertise in pharmaceutical sciences, chemistry, and process engineering with decades of experience in drug formulation and thin film production.
Driven by innovation and precision, we transform complex drug delivery challenges into scalable, market-ready solutions.

Wolfgang Wagner

Head of R&D / Project Management

Hugh Rogers

Managing Director

Part of BioNxt Solutions

As part of the BioNxt Solutions Group, Vektor Pharma plays a key role in developing advanced oral drug delivery technologies across the BioNxt portfolio.
Together, we bring new therapeutic possibilities to life — from concept to clinical application.

History

A Track Record of Pharmaceutical Innovation

2009
Foundation
Vektor Pharma TF GmbH is founded in Uttenweiler, Germany, with a mission to develop innovative pharmaceutical dosage forms and advanced drug delivery technologies.
2010
R&D Expansion
Establishment of dedicated formulation and analytical laboratories to support early-stage development of thin film and transdermal delivery systems.
2014
GMP Certification & API Licensing
Achieved GMP manufacturing authorization and obtained licenses to handle controlled substances — enabling the company to support clinical-grade and narcotic formulation development.
2015
Breakthrough in Film & Patch Technologies
Introduced proprietary coating and cutting processes for high-precision oral thin film and transdermal patch applications, positioning Vektor among Europe’s leading film formulation specialists.
2019
Integration into BioNxt Solutions Group
Acquired by BioNxt Solutions Inc. (formerly XPhyto Therapeutics Corp.), expanding access to international resources, new delivery programs, and R&D in emerging APIs including cannabinoid-based formulations.
2020–2022
Clinical Development & Innovation
Advanced several projects across oral thin film and transdermal platforms, including formulations for neurological and pain indications, while validating scalability under GMP conditions.
2023
Strategic Realignment
Focus shifted toward oral thin film (ODF) technology as the company’s core area of expertise — offering pharmaceutical partners a proven platform for precision dosing, rapid onset, and enhanced patient compliance.
Today
Leaders in Oral Thin Film Technology
Vektor Pharma is recognized as a European leader in oral thin film development, combining formulation science, engineering excellence, and regulatory experience to deliver next-generation drug delivery solutions.